97001 ⎘
Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans; Hormones Glucagons
Method for producing proteins in that lack detectable cross binding activity to antibodies against host cell antigens
#902Peptidic GLP-2 agonists
#903Process for solubilizing glucagon-like peptide 1 compounds
#904Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers
#905Glucagon analogs exhibiting physiological solubility and stability
#906GLP-1 analogues and their pharmaceutical salts and uses
#907Carrier immunoglobulins
#908Osmotic delivery comprising an insulinotropic peptide and uses thereof
#909Acylated glucagon analogues
#910GIP receptor-active glucagon compounds
#911OXYNTOMODULIN ANALOGS
#912METHOD FOR UNIVERSAL ENZYMATIC PRODUCTION OF BIOACTIVE PEPTIDES
#913PURIFICATION OF PEPTIDES PREPARED BY SOLID PHASE SYNTHESIS
#914Host cells and methods of use
#915Modified exendins and exendin agonists
#916Stable analogs of peptide and polypeptide therapeutics
#917GLP-1 ANALOGUES AND THEIR PHARMACEUTICAL SALTS AND USES
#918Glucagon antagonists
#919SELECTIVE AND POTENT PEPTIDE INHIBITORS OF Kv1.3
#920Glucose-dependent insulinotropic peptide analogs
#921Process for solubilizing glucagon-like peptide 1 compounds
#922Drug fusions and conjugates
#923Stabilized bioactive peptides and methods of identification, synthesis, and use
#924THERAPEUTIC METHOD FOR INCREASING PANCREATIC BETA CELL MASS
#925N-terminus conformationally constrained GLP-1 receptor agonist compounds
#926Albumin fusion proteins
#927Counter current purification of polypeptides
#928Peptidomimetics with glucagon antagonistic and GLP 1 agonistic activities
#929Selective glucagon-like-peptide-2 (GLP-2) analogues
#930EXENDINS AND EXENDIN AGONIST ANALOGS TO REGULATE GASTROINTESTINAL MOTILITY
#931Method for preparing a site-specific physiologically active polypeptide conjugate
#932PROCESS FOR THE PRODUCTION OF PREFORMED CONJUGATES OF ALBUMIN AND A THERAPEUTIC AGENT
#933REVERSED PHASE HPLC PURIFICATION OF A GLP-1 ANALOGUE
#934Pharmaceutical compositions
#935Glucagon analogues
#936Glucagon analogues
#937Glucagon analogues
#938Glucagon analogues
#939Methods for Lowering Plasma Glucagon with Exendins and Exendin Agonist Analogs
#940Commensal bacteria as signal mediators within a mammalian host
#941Methods of enhancing functioning of the large intestine
#942C-terminal fragments of glucagon-like peptide-1 (GLP-1)
#943GLP-1 ANALOGS AND USES THEREOF
#944Glucagon/GLP-1 receptor co-agonists
#945GLP-1 FUSION POLYPEPTIDES
#946Long-Acting GLP-1 Derivatives, and Methods of Treating Cardiac Dysfunction
#947Sugar chain added GLP-1 peptide
#948PEPTIDE AGONISTS OF GLP-1 ACTIVITY
#949METHOD FOR INTRODUCING DOTA
#950Peptides and methods for their preparation and use
#951GLP-I Agonist And Cardiovascular Complications
#952GLUCAGON-LIKE PEPTIDE-2 AND ITS THERAPEUTIC USE
#953Method of acylating a peptide or protein
#954INSULINOTROPIC PEPTIDE SYNTHESIS USING SOLID AND SOLUTION PHASE COMBINATION TECHNIQUES
#955Molecular probe for imaging of pancreatic islets and use of the same
#956PROCESS FOR PRODUCING PLANT STORAGE ORGAN WITH HIGH PRODUCTION OF RECOMBINANT PROTEIN AND NOVEL RECOMBINANT PROTEIN
#957Glycosylated GLP-1 peptide
#958Glucagon analogs exhibiting enhanced solubility and stability in physiological pH buffers
#959Pharmaceutical composition comprising oxyntomodulin derivatives and a method for reducing body weight using the composition
#960POLYMER CONJUGATES OF GLP-2-LIKE PEPTIDES
#961Double-acylated GLP-1 derivatives
#962GIP-based mixed agonists for treatment of metabolic disorders and obesity
#963Treatment of inflammatory bowel disease using glucagon-like-peptide-2 (GLP-2) analogues
#964Pharmaceutical compositions comprising GLP-1 peptides or extendin-4 and a basal insulin peptide
#965Oxyntomodulin peptide analogue
#966Oxyntomodulin peptide analogue
#967SHORTENED GLUCAGON-LIKE PEPTIDE 1(SGLP-1) PREPARATION METHOD AND APPLICATION
#968PEPTIDE AGONISTS OF GLP-1 ACTIVITY
#969DPP-IV resistant GIP hybrid polypeptides with selectable properties
#970Analogues of glucose-dependent insulinotropic polypeptide
#971Analogues of glucose-dependent insulinotropic polypeptide (GIP) modified at N-terminal
#972Analogues of glucose-dependent insulinotropic polypeptide
#973Method for enzymatic production of GLP-2(1-33) and GLP-2(1-34) peptides
#974GLP-1 fusion peptides, their production and use
#975Therapeutic agents comprising fusions of vasoactive intestinal peptide and elastic peptides
#976Efficient production of peptides
#977Methods and compositions for delivering peptides
#978Glucagon-like-peptide-2 (GLP-2) analogues
#979Peptide compounds exhibiting glucagon antagonist and GLP-1 agonist activity
#980PRODUCTION OF GLUCAGON LIKE PEPTIDE 2 AND ANALOGS
#981Glucagon-Like Peptide-1 derivatives and their pharmaceutical use
#982Modified Nucleotide Sequence Encoding Glucagon-Like Peptide-1 (GLP-1), Nucleic Acid Construct Comprising Same for Production of Glucagon-Like Peptide-1 (GLP-1), Human Cells Comprising Said Construct and Insulin-Producing Constructs, and Method of Use Thereof
#983LONG LASTING ANTI-ANGIOGENIC PEPTIDES
#984GLP-1 Derivatives II
#985PROCESS FOR SOLUBILIZING GLUCAGON-LIKE PEPTIDE 1 COMPOUNDS
#986PROCESS FOR THE PRODUCTION OF EXENATIDE AND OF AN EXENATIDE ANALOGUE
#987DRUG FUSIONS AND CONJUGATES
#988Glucagon-like peptide-2 analogs
#989Albumin fusion proteins
#990Glucose-regulating polypeptides and methods of making and using same
#991Method of Purifying a Peptide
#992Semi-recombinant preparation of GLP-1 analogues
#993Method for amidating polypeptides with basic amino acid C-terminals by means of specific endoproteases
#994Novel GLP-1 Derivatives
#995INSULINOTROPIC PEPTIDE SYNTHESIS USING SOLID AND SOLUTION PHASE COMBINATION TECHNIQUES
#996TRUNCATED GLP-1 DERIVATIES AND THEIR THERAPEUTICAL USE
#997Insulinotropic compounds and uses thereof
#998Compositions, methods and uses
#999PEPTIDES DERIVATIZED WITH A-B-C-D- AND THEIR THERAPEUTICAL USE
#1000GLP-1 Fusion Peptides, Their Production and Use
#1001Extended recombinant polypeptides and compositions comprising same
#1002Stable formulation of modified GLP-1
#1003HUMAN GLUCAGON-LIKE PEPTIDE-1 MIMICS AND THEIR USE IN THE TREATMENT OF DIABETES AND RELATED CONDITIONS
#1004Polymer conjugates of GLP-1
#1005N-terminal modified exendin-4
#1006Glucagon analogues
#1007Glucagon/GLP-1 receptor co-agonists
#1008Glucagon analogs exhibiting enhanced solubility in physiological pH buffers
#1009Purification of Glucagon-Like Peptides
#1010Stitched polypeptides
#1011Novel Plasma Protein Affinity Tags
#1012Process for the Preparation of a Peptide Powder Form
#1013Method of ameliorating symptoms of type 1-diabetes using GABA related compounds and GLP-1/exendin-4 compounds
#1014GLP-1 Fusion Peptides Conjugated to Polymer(s), Their Production and Use
#1015Pharmaceutical composition comprising oxyntomodulin derivatives and a method for reducing body weight using the composition
#1016In Vivo Production and Delivery of Erythropoietin or Insulinotropin for Gene Therapy
#1017Methods of making proteins and peptides containing a single free cysteine
#1018Methods of enhancing functioning of the large intestine
#1019Insulinotropic complex using an immunoglobulin fragment
#1020Method for producing acylated peptides
#1021Protracted GLP-1 Compositions
#1022Methods and compositions for delivering peptides
#1023Lactococcus promoters and uses thereof
#1024Biosynthetic Polypeptides Utilizing Non-Naturally Encoded Amino Acids
#1025GLP-1 compounds
#1026Fragments of the Glucagon-Like Peptide-1 and Uses Thereof
#1027Polypeptide Protracting Tags
#1028Composition and Methods for Treatment of Congestive Heart Failure
#1029Sustained release glp-1 receptor modulators
#1030Therapeutic agents comprising a GLP-1 receptor agonist and elastin-like peptide
#1031Glycosilated Peptide and Medicine Comprising It as an Effective Ingredient
#1032Glucagon-Like Peptides and Uses Thereof
#1033HUMAN GLP-1 MIMETIBODIES, COMPOSITIONS, METHODS AND USES
#1034Acylated Exendin-4 Compounds
#1035LONG LASTING GLUCAGON-LIKE PEPTIDE 2 (GLP-2) FOR THE TREATMENT OF GASTROINTESTINAL DISEASES AND DISORDERS
#1036Stabilized GLP-1 analogs
#1037OXYNTOMODULIN ANALOGUES AND THEIR EFFECTS ON FEEDING BEHAVIOUR
#1038Methods for identifying a GLP-1 secretagogue
#1039Insulinotropic peptide synthesis using solid and solution phase combination techniques
#1040Synthesis of glucagon-like peptide
#1041AGGREGABLE GLP-1 ANALOGUE AND SUSTAINED-RELEASE PHARMACEUTICAL COMPOSITION
#1042GLP-1 ANALOG FUSION PROTEIN FORMULATIONS
#1043GLP-1 gene delivery for the treatment of type 2 diabetes
#1044Oral glucagon-like peptide conjugates for metabolic diseases
#1045GLP-1 pegylated compounds
#1046Lyophilized formulations of exendins and exendin agonist analogs
#1047GLP-I Agonist And Cardiovascular Complications
#1048Methods to restore glycemic control
#1049Analogues of GLP-1
#1050Chronic treatment regimen using glucagon-like insulinotropic peptides
#1051GLP/1/exendin 4 IgG Fc fusion constructs for treatment of diabetes
#1052Compounds and their effects on feeding behaviour
#1053Peptide derivatives of exendin-4
#1054Derivatives of GLP-1 analogs
#1055CHIMERIC THERAPEUTIC AGENTS
#1056Methods and DNA constructs for high yield production of polypeptides
#1057Exendins and exendin agonist analogs to regulate gastrointestinal motility
#1058Acylated GLP-1 compounds
#1059Insulinotropic peptide synthesis using solid and solution phase combination techniques
#1060GLP-1 ANALOGUES
#1061Glucagon analogs exhibiting physiological solubility and stability
#1062Shortened glucagon-like peptide 1(sGLP-1) preparation method and application
#1063GLP-2 mimetibodies, polypeptides, compositions, methods and uses
#1064Stable Formulation of Modified GLP-1
#1065Sugar chain added GLP-1 peptide
#1066Albumin Fusion Proteins
#1067GLUCAGON-LIKE PROTEIN-1 RECEPTOR (GLP-1R) AGONIST COMPOUNDS
#1068Albumin Fusion Proteins
#1069CONJUGATE OF WATER-SOLUBLE HYALURONIC ACID MODIFICATION PRODUCT WITH GLP-A ANALOGUE
#1070Long lasting synthetic exendin-4 peptide conjugates and methods of use thereof
#1071GLP-1 analog fusion proteins
#1072Dimeric Peptide Agonists of the Glp-1 Receptor
#1073GIP analog and hybrid polypeptides with selectable properties
#1074Composition and method for prevention and treatment of type I diabetes
#1075NOVEL GLP-1 ANALOGUES LINKED TO ALBUMIN-LIKE AGENTS
#1076Method for producing carboxy-terminal-amidified peptides
#1077Stabilized bioactive peptides and methods of identification, synthesis, and use
#1078GIP analog and hybrid polypeptides with selectable properties
#1079Adjuvant Activity of Gastrointestinal Peptides
#1080Branched Peg Remodeling and Glycosylation of Glucagon-Like Peptides-1 [Glp-1]
#1081Modified nucleotide sequence encoding glucagon-like peptide-1 (GLP-1), nucleic acid construct comprising same for production of glucagon-like peptide-1 (GLP-1), human cells comprising said construct and insulin-producing constructs, and methods of use thereof
#1082Ion exchange chromatography of GLP-1, analogs and derivatives thereof
#1083Suspension formulations of insulinotropic peptides and uses thereof
#1084Exendin Analog Formulations
#1085Composition for the therapy of diabetes mellitus and adiposity
#1086HUMAN GLUCAGON-LIKE-PEPTIDE-1 MODULATORS AND THEIR USE IN THE TREATMENT OF DIABETES AND RELATED CONDITIONS
#1087Exendins and exendin agonists modified with albumin
#1088Albumin fusion proteins
#1089Intraoral dosage forms of glucagon
#1090Extended GLP-1 compounds
#1091Exendins and exendin agonists modified with polyamino acids
#1092Specific antagonists for glucose-depenent insulinotropic polypeptide (GIP)
#1093Protracted GLP-1 compounds
#1094Methods of treating diabetes with albumin-conjugated exendin peptides
#1095Albumin Fusion Proteins
#1096Albumin fusion proteins comprising insulin polypeptides
#1097Stable formulation of modified GLP-1
#1098Albumin Fusion Proteins
#1099G-CSF-albumin fusion proteins
#1100Method for universal enzymatic production of bioactive peptides
#1101Albumin fusion proteins
#1102Specific antagonists for glucose-dependent insulinotropic polypeptide (GIP)
#1103Stable Formulations Of Peptides
#1104Polyethylene glycol linked GLP-1 compounds
#1105Analogues of GLP-1
#1106GLP-1 derivatives II
#1107Bacterial host cell for the direct expression of peptides
#1108Bacterial host cell for the direct expression of peptides
#1109Bacterial host cell for the direct expression of peptides
#1110Bacterial host cell for the direct expression of peptides
#1111Stable analogs of peptide and polypeptide therapeutics
#1112N-terminally modified GLP-1 receptor modulators
#1113GLP-2 Derivatives
#1114Pharmaceutical composition comprising a human GLP-1 mimetibody
#1115Method For Producing Acylated Peptides
#1116Glp- (9-36) Methods and Compositions
#1117Insulinotropic peptide synthesis using solid and solution phase combination techniques
#1118Pharmaceutical Composition for Lowering Blood Sugar Level
#1119HUMAN GLUCAGON-LIKE PEPTIDE-1 MIMICS AND THEIR USE IN THE TREATMENT OF DIABETES AND RELATED CONDITIONS
#1120Process for the production of preformed conjugates of albumin and a therapeutic agent
#1121Albumin fusion proteins
#1122Fusion Proteins
#1123Albumin fusion proteins
#1124HUMAN GLUCAGON-LIKE-PEPTIDE-1 MODULATORS AND THEIR USE IN THE TREATMENT OF DIABETES RELATED CONDITIONS
#1125Glucagon-like-peptide-2 (GLP-2) analogues
#1126GLP-2 Mimetibodies, Polypeptides, Compositions, Methods and Uses
#1127Stimulation of beta cell proliferation
#1128Novel Glp-1 Derivatives
#1129Specific antagonists for glucose-dependent insulinotropic polypeptide (GIP)
#1130USE OF GLP-1 ANALOGS AND DERIVATIVES ADMINISTERED PERIPHERALLY IN REGULATION OF OBESITY
#1131Specific antagonists for glucose-dependent insulinotropic polypeptide (GIP)
#1132Specific antagonists for glucose-dependent insulinotropic polypeptide (GIP)
#1133GLP-1 FUSION PROTEINS
#1134Human GLP-1 mimetibodies, compositions, methods and uses
#1135Methods of enhancing functioning of the large intestine
#1136GLP-1 agonists, compositions, methods and uses
#1137Methods of treating chemotherapy-induced diarrhea/mucositis using glucagon-like-peptide-2(GLP-2)analogues
#1138Peptide agonists of GLP-1 activity
#1139Plasma protein affinity tags
#1140Novel GLP-1 analogues linked to albumin-like agents
#1141Dipeptidyl-peptidase protected protein
#1142GLP-1 agonist and cardiovascular complations
#1143Novel GLP-1 compounds
#1144Analogues of GLP-1
#1145GLP-1 analog fusion proteins
#1146GLP-1 derivative
#1147N-terminally modified GLP-1 receptor modulators
#1148Hybrid polypeptides having glucose lowering activity
#1149Human glucagon-like-peptide-1 modulators and their use in treatment of diabetes and related conditions
#1150Albumin fusion proteins
#1151Method of treating a subject suffering stroke comprising administering Glucagon-like peptide-1 analogs
#1152Modified glucagon-like peptide-1 analogs
#1153Glucagon-like peptide-1 analogs
#1154Long lasting glucagon-like peptide 2 (GLP-2) for the treatment of gastrointestinal diseases and disorders
#1155Analogues of glp-1
#1156Purification of glucagon-like peptides
#1157Modified transferrin fusion proteins
#1158Derivatives of GLP-1 analogs
#1159Albumin fusion proteins
#1160GLP-1 derivative and preparation thereof absorbable via mucous membrane
#1161Separation of polypeptides comprising a racemized amino acid
#1162Methods and compositions for preparing peptides with excellent solubility characteristics in aqueous solution at physiological pH
#1163Long lasting anti-angiogenic peptides
#1164Methods involving long lasting synthetic exendin-4 peptide conjugates
#1165Methods for increasing the production of a recombinant polypeptide from a host cell
#1166Glucagon-like peptide-2 and its therapeutic use
#1167GLP-2 derivatives
#1168Stabilized bioactive peptides and methods of identification, synthesis, and use
#1169Hybrid polypeptides with selectable properties
#1170Stable pharmaceutical compositions
#1171Transepithelial delivery of peptides with incretin hormone activities
#1172Exendin analog formulations
#1173Methods involving long lasting synthetic exendin-4-peptide conjugates
#1174Method for enzymatic production of GLP-2(1-33) and GLP-2(1-34) peptides
#1175Biosynthetic polypeptides utilizing non-naturally encoded amino acids
#1176Glucagon-like peptide-1 analogs with long duration of action
#1177Extended glucagon-like peptide-1 analogs
#1178Long lasting synthetic exendin-4 peptide conjugates
#1179Method for universal enzymatic production of bioactive peptides
#1180Peptides acting as both GLP-1 receptor agonists and glucagon receptor antagonists and their pharmacological methods of use
#1181Peptides acting as both GLP-1 receptor agonists and glucagon receptor antagonists and their pharmacological methods of use
#1182Prolonged delivery of peptides
#1183Peptides acting as both GLP-1 receptor agonists and glucagon receptor antagonists and their pharmacological methods of use
#1184Peptides acting as both GLP-1 receptor agonists and glucagon receptor antagonists and their pharmacological methods of use
#1185Peptides acting as both GLP-1 receptor agonists and glucagon receptor antagonists and their pharmacological methods of use
#1186Peptides acting as both GLP-1 receptor agonists and glucagon receptor antagonists and their pharmacological methods of use
#1187Method for making acylated polypeptides
#1188Modified exendins and exendin agonists
#1189Method for enzymatic production of GLP-1 (7-36) amide peptides
#1190Methods and DNA constructs for high yield production of polypeptides
#1191Analogues of GLP-1
#1192Peptide compositions with effects on blood glucose
#1193Methods and DNA constructs for high yield production of polypeptides
#1194Bacterial host cell for the direct expression of peptides
#1195Albumin fusion proteins comprising GLP-1 polypeptides
#1196Production of glucagon-like peptide 2
#1197Peptides acting as both GLP-1 receptor agonists and glucagon receptor antagonists and their pharmacological methods of use
#1198Novel analogues of glucose-dependent insulinotropic polypeptide
#1199In vivo production and delivery of erythropoietin or insulinotropin for gene therapy
#1200Composition for the therapy of diabetes mellitus and adiposity